There is little evidence that treatment of patients with Barrett's esophagus with proton pump inhibitors (PPIs) over periods up to 6 years results in major regression of Barrett's.
Dr Cooper and colleagues determined if longer periods of treatment with PPIs lead to significant regression of Barrett's.
The researchers determined the incidence of esophageal adenocarcinoma in the PPI-treated patients.
The team analyzed prospectively-collected data on Barrett's esophagus patients treated with PPI for 1 to 13 years.
|During treatment but 48% of patients developed squamous islands|
|Alimentary Pharmacology & Therapeutics|
The team treated 188 patients with Barrett's esophagus and intestinal metaplasia, for 1 to 13 years with a PPI.
No change in length was seen during treatment but 48% of patients developed squamous islands.
Squamous islands correlated with treatment duration and male sex but not with PPI dose or patient age.
The researchers noted that 6 patients developed dysplasia and 3 males developed adenocarcinoma during treatment.
Dr Cooper's team concluded, “Proton-pump inhibitor treatment over 1 to 13 years does not shorten the Barrett's esophagus segment but squamous islands appear in many patients.”
“The incidence of oesophageal adenocarcinoma was low in these proton pump inhibitor-treated patients compared with published series.”